-
Product Insights
Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Glioblastoma Multiforme (GBM) - Drugs In Development, 2023’, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Mycobacterium tuberculosis Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Mycobacterium tuberculosis Infections - Drugs In Development, 2023’, provides an overview of the Mycobacterium tuberculosis Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mycobacterium tuberculosis Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Tuberculosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Tuberculosis - Drugs In Development, 2023’, provides an overview of the Tuberculosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TVI-Brain-1 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TVI-Brain-1 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TVI-Brain-1 in Glioblastoma Multiforme (GBM) Drug Details: TVI-Brain-1 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TVI-Brain-1 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TVI-Brain-1 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TVI-Brain-1 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: TVI-Brain-1 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INCB-123667 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - INCB-123667 in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INCB-123667 in Esophageal Cancer Drug Details: INCB-123667 is under development for the...
-
Product Insights
Colon Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Colon Cancer Pipeline Drugs Market Overview Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools, and weight loss with...
-
Product Insights
Glioblastoma Multiforme (GBM) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Glioblastoma Multiforme Pipeline Drugs Market Glioblastoma also known as glioblastoma multiforme is a fast-growing glioma that develops from star-shaped glial cells that support the health of the nerve cells within the brain. Symptoms include headaches, blurred vision, nausea, vomiting, memory loss, speech difficulty, muscle weakness, and loss of appetite. Risk factors include gender (male) and age. Treatment includes surgery, radiation therapy, and chemotherapy. The Glioblastoma Multiforme (GBM) drugs in development market research report provides comprehensive information on the therapeutics under...
-
Product Insights
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Products Market Report Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – TVI-Leukemia-1
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry TVI-Leukemia-1 Drug Details TVI-Leukemia-1 is under development for the treatment of leukemia. It is...